The first generation of cephalosporins has a broad antibacterial spectrum and strong activity against Gram-positive bacteria. It is sensitive to penicillinase-producing and non-penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococci, Streptococcus pyogenes, Streptococcus pneumoniae, group B hemolytic Streptococcus, viridans streptococci, Staphylococcus epidermidis, Corynebacterium diphtheriae, and Bacillus anthracis; Haemophilus influenzae, Neisseria meningitidis, Moraxella catarrhalis, and Neisseria gonorrhoeae are highly sensitive; some strains of Escherichia coli, Klebsiella, Salmonella, Shigella, and Proteus are moderately sensitive; most of the remaining Gram-negative rods are resistant. Gram-positive anaerobic bacteria are sensitive, and Bacteroides fragilis is resistant. It mainly inhibits the synthesis of bacterial cell walls.

It has a broad spectrum of antibacterial activity against Gram-positive and Gram-negative bacteria, especially against Escherichia coli, Klebsiella, Haemophilus influenzae, Proteus and Bacteroides fragilis. Its mechanism of action is that it shows a strong affinity for penicillin-binding protein, which is the usual point of action of beta-lactam antibiotics, inhibits cell wall synthesis, binds to peptidoglycan, inhibits the binding of peptidoglycan to lipoprotein to promote bacteriolysis, and shows a strong bactericidal effect in a short time. This product shows antibacterial effect on bacteria during the proliferation period and the early stage of the stable period, and has a bactericidal effect at concentrations lower than the MIC, and lyses bacteria in a short time. The antibacterial effect in vivo is stronger than the prediction of MIC.

It exerts its antibacterial activity by inhibiting the synthesis of bacterial cell walls, and has antibacterial activity against aerobic Gram-positive bacteria (such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes) and aerobic Gram-negative bacteria (such as Escherichia coli, Klebsiella pneumoniae, Proteus).

It exerts antibacterial activity by inhibiting the synthesis of bacterial cell walls. It has antibacterial activity against aerobic Gram-positive bacteria (such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes) and aerobic Gram-negative bacteria (such as Escherichia coli, Klebsiella pneumoniae, Proteus).

It exerts its antibacterial activity by inhibiting the synthesis of bacterial cell walls, and has antibacterial activity against aerobic Gram-positive bacteria (such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes) and aerobic Gram-negative bacteria (such as Escherichia coli, Klebsiella pneumoniae, Proteus).